2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1425

Update from the Juvenile Scleroderma Inception Cohort
Abstract Number: 1426

The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Abstract Number: 1427

A New Model of Care for Pediatric Rheumatology in Ontario: Preliminary Results from Pilot Telemedicine Clinics Utilizing Advanced Clinician Practitioners in Arthritis Care
Abstract Number: 1428

Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases
Abstract Number: 1429

A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center
Abstract Number: 1430

Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease
Abstract Number: 1431

Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center
Abstract Number: 1432

Engaging Patients and Parents to Improve Mental Health for Youth with Rheumatologic Disease
Abstract Number: 1433

The Role of Patient and Parental Resilience in Amplified Musculoskeletal Pain Syndrome
Abstract Number: 1434

Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome
Abstract Number: 1435

Hormonal Contraception Use and Capacity to Self-Screen for Contraindications Among Adolescents in a Pediatric Rheumatology Clinic
Abstract Number: 1436

Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study
Abstract Number: 1437

Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India
Abstract Number: 1438

Treatment and Response of Down Syndrome Arthropathy
Abstract Number: 1439

Yellow Fever Vaccination in Brazil: Short-Term Safety in Pediatric Autoimmune Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].